Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship

DUBLIN, Ireland, Nov. 18, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, emphasized the significance of the new updated report from the Centers for Disease Control and Prevention (CDC) concerning the rise of antibiotic resistance.